HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genetics of pain, opioids, and opioid responsiveness.

Abstract
Pain is an integral part of the defense mechanisms required for survival. Several hereditary syndromes of complete or almost complete insensitivity to pain have been identified and include channelopathy-associated pain insensitivity, of which the most likely candidate gene is the α-subunit of the voltage-gated sodium channel known as Na(v)1.7. Five hereditary sensory and autonomic neuropathy syndromes have been described. Variable pain sensitivity in the general population has been linked to common variants of the μ-opioid receptor and of the catecholamine-O-methyltransferase genes potentially leading to increased opioid tonus. Variants of the guanosine triphosphate cyclohydrolase 1/dopa-responsive dystonia gene appear to regulate nociception. Other candidate genes are the transient receptor potential cation channel, subfamily 5 member 1, gene and the melanocortin-1 receptor gene. Candidate genes for predicting opioid efficacy are drug-metabolizing enzymes and transporters-including cytochrome P450, uridine 5'-diphosphate-glucuronosyltransferases, and adenosine triphosphate-binding cassette transporters-that are involved in opioid metabolism. Most current knowledge on the genetic regulation of pain has been derived from animal models developed mainly in mice. Genomics has the potential to contribute to therapeutic advances with the promising approach of using small interfering RNA in the control of neuropathic pain. Knowledge of the genetic factors that affect opioid efficacy, metabolism, and adverse effects has the potential for personalizing both acute and chronic pain management, and for designing more useful opiate pain medications with lower adverse event profiles.
AuthorsJohanne Tremblay, Pavel Hamet
JournalMetabolism: clinical and experimental (Metabolism) Vol. 59 Suppl 1 Pg. S5-8 (Oct 2010) ISSN: 1532-8600 [Electronic] United States
PMID20837195 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Analgesics, Opioid
  • NAV1.7 Voltage-Gated Sodium Channel
  • SCN9A protein, human
  • Sodium Channels
Topics
  • Analgesics, Opioid (therapeutic use)
  • Animals
  • Disease Models, Animal
  • Hereditary Sensory and Autonomic Neuropathies (genetics)
  • Humans
  • NAV1.7 Voltage-Gated Sodium Channel
  • Pain (drug therapy, genetics)
  • Pain Threshold
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide
  • Precision Medicine
  • Sodium Channels (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: